Hitiq Limited · ASX:HIQ
Hitiq — Investor Presentation (October 2025)
16 slides from Hitiq's investor presentation, Oct 15, 2025
Slide 1: US Roadshow – Presentation Slides (ASX Announcement)
ASX ANNOUNCEMENT ASX: HIQ 15 October 2025 US Roadshow – Presentation Slides HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a leader in concussion management technology, advises Executive Chair, Earl Eddings, and Non-Executive Director Matthew Clayworth will be undertaking a roadshow to potential i
Slide 2: End-to-End Brain-Health Surveillance & Management
Private and confidential, commercial in confidence Concussion Management System For personal use only End-to-End Brain-Health Surveillance & Management Turning head-impact data into safer decisions October 2025 Earl Eddings- Executive Chairman Email: earl@hitiq.co
Slide 3: Disclaimer
Disclaimer This presentation is not an offer for financial products in any jurisdiction or a financial product recommendation. The infor mation in this presentation is an overview and does not contain all information necessary for investment decisions. In making investment decisions in connection wi
Slide 4: Executive Summary
1 Executive Summary Data flywheel advantage in a multi-billion US sports health market. 1. What We Do – 2. Why Now & Why Us 3. US Go-to-Market 4. Market & Plan Brain-Health The Reset + Proof Consumer → Multi-Billion US Surveillance Schools/Clubs → Opportunity, Clear • Reset: New leadership; Leagues
Slide 5: The Problem: head impacts are missed, decisions lack objective data
2 The Problem: head impacts are missed, decisions lack objective data The Problem: A Crisis in Grassroots Sports • Fear of concussion is driving declines in youth sport participation. [4][5] • 100,000+ concussions annually in Australia; up to 70% go undetected. [1] • Parents and clubs are losing con
Slide 6: Why Now? scalable tech, consumer go-live, and policy pressure
3 Why Now? scalable tech, consumer go-live, and policy pressure Sports procurement is seasonal and multi-stakeholder. Our plan begins consumer/grassroots first where adoption cycles are shortest, then leverages data & trust to enter leagues 1. Breakthrough Innovation 2. Consumer Product Just 3. Poli
Slide 7: Product Snapshot
4 Product Snapshot World first, end-to-end concussion management solution, empowering athletes to play with confidence and giving parents peace of mind. Secure, Scalable Analytics – powering athlete, club & industry insights How works For personal use only 1. Detect 2. Assess 3. Manage Embedded sens
Slide 8: US Market + Global Growth Opportunity
5 US Market + Global Growth Opportunity For personal use only Single PROTEQT Purchase TAM~$5.0B — pricing $250 device. [13][14][15][16][17] Annual Ongoing Subscription TAM ~$2.1B/yr — pricing $100 ARPU. [13][16][17] US 5-Year Modelling (100k Baseline units per year) ≈ $198.2M • 100k units/yr): $250
Slide 9: Validation: Lab, Field, Biomarkers, Battle-tested tech
6 Validation: Lab, Field, Biomarkers, Battle-tested tech PROTEQT technology was forged and battle-tested in the arena of professional collision sports globally. Lab Validation Field Validation Biomarker Validation Battle Tested in the Pros. Proven At Scale • Independently tested at Virginia • Proven
Slide 10: The MOAT
7 The MOAT A defensible end-to-end system: exclusive hardware + proprietary data + integrated software at retail scale Exclusive For personal use only Hardware ✓ Exclusive global Only scalable boil-and-bite at partnership with Shock volume → immediate use vs Doctor. custom-lab weeks Integrated Propr
Slide 11: Defensible Competitive Advantage
8 Defensible Competitive Advantage Competitor Market reality Implications • Two players: HITIQ (boil-and-bite; immediate fit; scalable) vs Prevent • First to mass adoption wins the data flywheel → better models → better UX (custom-lab; multi-week workflow).[12] → more league leverage. For personal u
Slide 12: Activation to Adoption: US GTM & Proof
9 Activation to Adoption: US GTM & Proof Cracking sport with a US-first playbook: instant boil-and-bite activation → grassroots proof → league leverage. 1. Why now 2. US GTM motion 3. Proof so far 4. Adoption signals • Sport is hard to sell into • Consumer retail & e-comm — • Consumer product launch
Slide 13: Roadmap, Revenue Mix & Use of Funds
10 Roadmap, Revenue Mix & Use of Funds We’ll drive US-first growth by seeding users with hardware, compounding high-margin subscriptions, and deploying funding into GTM, manufacturing scale, product/data, and clinical proof to deliver scaled consumer & schools/clubs, signed league pilots, Stage-2 CO
Slide 14: Candid Context & Risk Mitigation
11 Candid Context & Risk Mitigation We’ve reset the company (new leadership, scalable consumer product) and are now executing a US-first brain-health surveillance strategy—driving off-season league pilots, education/telehealth adoption, a steady validation cadence, Stage-2 COGS + software mix improv
Slide 15: Board & Management
12 Board & Management Execution is about people. We have experienced leadership, global expansion capability, and governance that reduces execution risk Earl Eddings Jennifer Tucker Phil Carulli Matthew Clayworth James Barrie Board Executive Chairman Non-Executive Director Non-Executive Chairman Non
Slide 16: Thank You
Thank You For personal use only Earl Eddings- Executive Chairman Email: earl@hitiq.co Address: Unit 4/38-42 White Street, South Melbourne. 3205, Victoria